IFPMA Visits Supreme People's Court Intellectual Property Court
IFPMA delegates met with Supreme People's Court IP Court leaders to discuss pharmaceutical patent linkage, preliminary injunctions, and enforcement mechanisms.
WISECODE Take
On October 30, 2026, IFPMA Director General Andrew Jenner visited China's Supreme People's Court IP Court. Rather than endorsement, this meeting reflects multinational pharma's efforts to advocate for clearer patent linkage and preliminary injunction standards. Deputy Judge Zhu Li highlighted representative cases on patent linkage, signaling a shift toward proactive litigation strategies. Unrelated non-biomedical firms remain unaffected. For pharma entities entering China, tracking court precedents on preliminary injunctions and conducting Freedom-to-Operate (FTO) analyses are vital steps.
Original sources
Compiled automatically by WISECODE IP Radar. Summaries are short source excerpts; commentary is AI-generated. See the source links for full text.
How does this affect your company?
WISECODE assesses IP risk and helps you decide what the news means for your next step.